Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Briacell Therapeutics Corp
NASDAQ BCTX
Data sourced from
and
and
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending January 31, 2024: USD -0.32
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted is USD -0.32 for the Trailing 12 Months (TTM) ending January 31, 2024, a 85.54% change year over year. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities.
-
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending January 31, 2023 was USD -2.18, a -2,192.35% change year over year.
-
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending January 31, 2022 was USD -0.10, a 99.99% change year over year.
-
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending January 31, 2021 was USD -955.03, a -36,518.09% change year over year.
-
Briacell Therapeutics Corp Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending January 31, 2020 was USD -2.61.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: BCTX
| CEO | Dr. William V. Williams M.D. |
| IPO Date | Feb. 24, 2021 |
| Location | Canada |
| Headquarters | Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 |
| Employees | 16 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email